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A bs tr ac t
Background
Primary debulking surgery before initiation of chemotherapy has been the standard 
of care for patients with advanced ovarian cancer.
Methods
We randomly assigned patients with stage IIIC or IV epithelial ovarian carcinoma, 
fallopian-tube carcinoma, or primary peritoneal carcinoma to primary debulking 
surgery followed by platinum-based chemotherapy or to neoadjuvant platinum-based 
chemotherapy followed by debulking surgery (so-called interval debulking surgery).
Results
Of the 670 patients randomly assigned to a study treatment, 632 (94.3%) were eligible 
and started the treatment. The majority of these patients had extensive stage IIIC 
or IV disease at primary debulking surgery (metastatic lesions that were larger than 
5 cm in diameter in 74.5% of patients and larger than 10 cm in 61.6%). The largest 
residual tumor was 1 cm or less in diameter in 41.6% of patients after primary 
debulking and in 80.6% of patients after interval debulking. Postoperative rates of 
adverse effects and mortality tended to be higher after primary debulking than 
after interval debulking. The hazard ratio for death (intention-to-treat analysis) in 
the group assigned to neoadjuvant chemotherapy followed by interval debulking, as 
compared with the group assigned to primary debulking surgery followed by chemo-
therapy, was 0.98 (90% confidence interval [CI], 0.84 to 1.13; P = 0.01 for non-
inferiority), and the hazard ratio for progressive disease was 1.01 (90% CI, 0.89 to 
1.15). Complete resection of all macroscopic disease (at primary or interval surgery) 
was the strongest independent variable in predicting overall survival.
Conclusions
Neoadjuvant chemotherapy followed by interval debulking surgery was not inferior 
to primary debulking surgery followed by chemotherapy as a treatment option for 
patients with bulky stage IIIC or IV ovarian carcinoma in this study. Complete resec-
tion of all macroscopic disease, whether performed as primary treatment or after 
neoadjuvant chemotherapy, remains the objective whenever cytoreductive surgery 
is performed. (Funded by the National Cancer Institute; ClinicalTrials.gov number, 
NCT00003636.)
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITA STUDI DI TORINO on October 31, 2012. For personal use only. No other uses without permission. 
 Copyright © 2010 Massachusetts Medical Society. All rights reserved. 
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 363;10 nejm.org september 2, 2010944
In most women with ovarian carcino-ma, the disease is not diagnosed until it is at an advanced stage. Primary cytoreductive sur-
gery is considered the standard of care for ad-
vanced ovarian carcinoma.1-4 However, data from 
prospective, randomized, controlled trials assess-
ing the role of primary surgery in the treatment 
of such cases are lacking. Interval debulking sur-
gery has not been viewed as beneficial in women 
with residual tumor that exceeds 1 cm in diameter 
after primary debulking surgery performed with 
the objective of maximal surgical effort by a gyne-
cologic oncologist.5-7 As an alternative to primary 
debulking surgery followed by chemotherapy, 
some authors have investigated the use of neoad-
juvant chemotherapy before cytoreductive surgery. 
However, results of a meta-analysis involving 835 
patients suggested that neoadjuvant chemother-
apy, as compared with primary debulking sur-
gery, was associated with a worse outcome.8
We report on a randomized trial in which we 
compared primary debulking surgery followed by 
platinum-based chemotherapy and platinum-based 
neoadjuvant chemotherapy followed by interval 
debulking surgery and additional platinum-based 
chemotherapy in women with advanced ovarian 
carcinoma.
Me thods
Patients
Eligible patients had biopsy-proven stage IIIC or 
IV invasive epithelial ovarian carcinoma, primary 
peritoneal carcinoma, or fallopian-tube carci-
noma. If a biopsy specimen was not available, a 
fine-needle aspirate showing an adenocarcinoma 
was acceptable under the following conditions: 
the presence of a pelvic (ovarian) mass; the pres-
ence of metastases outside the pelvis measuring 
at least 2 cm in diameter (as noted during diag-
nostic laparoscopy or laparotomy or on computed 
tomography [CT]); regional lymph-node metas-
tasis or proof of stage IV disease; and a ratio of 
cancer antigen 125 (CA-125, measured in kilounits 
per liter) to carcinoembryonic antigen (CEA, mea-
sured in nanograms per milliliter) that was great-
er than 25. The CA-125:CEA ratio has been shown 
to be useful for ruling out primary gastrointesti-
nal tumors that have metastasized to the perito-
neum, the ovaries, or both.9 If the serum CA-125: 
CEA ratio was 25 or lower, results of a barium 
enema (or colonoscopy), gastroscopy (or radio-
logic examination of the stomach), and mammog-
raphy (performed within 6 weeks before random-
ization) had to be negative for the presence of a 
primary tumor. Additional prerandomization re-
quirements included a World Health Organiza-
tion (WHO) performance status of 0 (asymptom-
atic) to 2 (symptomatic, in bed for less than half 
the day)10 and the absence of serious disabling 
diseases that would contraindicate primary cyto-
reductive surgery or platinum-based chemother-
apy. (Other inclusion criteria are listed in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org.) Before receiving 
treatment, all patients provided written informed 
consent. Because of an allegation of ethical irreg-
ularities at one of the centers with regard to an-
other European Organization for Research and 
Treatment of Cancer (EORTC) protocol, all the 
patients from that center who were enrolled in 
this study were excluded from the analysis.
Study Design
Patients had to start the assigned treatment within 
3 weeks after the initial biopsy or fine-needle as-
piration. The biopsy could be image-guided or 
carried out during laparoscopy or laparotomy. 
Patients who underwent laparotomy or laparos-
copy were not allowed to undergo any procedures 
other than the diagnostic biopsies. Randomiza-
tion was done centrally at the EORTC headquar-
ters after stratification, with the use of a mini-
mization technique to stratify for institution, 
method of biopsy (image-guided, laparoscopy, 
laparotomy, or fine-needle aspiration), tumor stage 
(IIIC or IV), and largest preoperative tumor size 
(excluding ovaries) (≤5 cm, >5 to 10 cm, >10 to 
20 cm, or >20 cm).
Patients were randomly assigned either to pri-
mary debulking surgery followed by at least six 
courses of platinum-based chemotherapy or to 
three courses of neoadjuvant platinum-based che-
motherapy followed by interval debulking surgery 
in all patients with a response or stable disease, 
followed in turn by at least three courses of 
platinum-based chemotherapy. In patients random-
ly assigned to primary debulking whose surgery 
was completed without optimal cytoreduction, 
interval debulking surgery was permitted if sta-
ble disease or a response was documented, and 
these patients were included in the primary-sur-
gery group for analyses. After the results of the 
Gynecologic Oncology Group trial (GOG-152) 
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(NCT00002568) were published,6 interval debulk-
ing surgery was no longer recommended for 
patients in whom optimal cytoreduction was not 
achieved despite a maximal effort at primary 
debulking surgery. Data on the timing of interval 
debulking surgery and chemotherapy, chemother-
apy regimens, and assessments are provided in 
the Supplementary Appendix. All surgical proce-
dures had to be performed by qualified gyneco-
logic oncologists who were appointed by the indi-
vidual institutions before the start of the study, 
and all patients were evaluated for eligibility 
before randomization, with no additional selec-
tion criteria (including resectability) imposed by 
the surgeon. No CT or laparoscopic scoring sys-
tems were used in the selection of the patients.
The study was designed and the manuscript 
written by the first author in cooperation with 
the other authors. Data were gathered at the 
EORTC headquarters and analyzed in cooperation 
with the authors by the EORTC statistician, who 
vouches for the accuracy of the data and the 
analyses. The decision to submit the manuscript 
for publication was made by the authors in agree-
ment with the EORTC–Gynaecological Cancer 
Group (EORTC-GCG) and the National Cancer 
Institute of Canada (NCIC) Clinical Trials Group. 
The study was approved by the EORTC Protocol 
Review Committee, the NCIC Clinical Trials Group 
Clinical Trials Committee, and the institutional 
review board of each participating institution. 
An independent data and safety monitoring com-
mittee was appointed to monitor the recruitment 
rate, the potential toxicity of the treatments, and 
the optimal percentage of debulking. The drugs 
administered for adjuvant chemotherapy were 
purchased by the individual institutions. The 
study was conducted in accordance with the pro-
tocol as amended. (The trial protocol is available 
at NEJM.org.)
Evaluation and Follow-up
Patients filled out two EORTC quality-of-life ques-
tionnaires at five time points during the study: 
EORTC QLQ-C30 (http://groups.eortc.be/qol/
questionnaires_qlqc30.htm) and QLQ-Ov28 (http://
groups.eortc.be/qol/downloads/modules/specimen 
_20qlq_ov28.pdf).
Tumor response during chemotherapy was 
evaluated according to the WHO criteria.11 In 
addition, progression of disease after first-line 
chemotherapy was defined by an increase by a 
factor of at least 2 in the nadir serum CA-125 
level according to the Gynaecologic Cancer Inter-
group criteria.12
Statistical Analysis
The primary end point of the study was overall 
survival. The group undergoing primary debulk-
ing surgery was considered to be the standard-
treatment group. On the basis of the earlier expe-
rience of the EORTC institutions, about 50% of 
patients with stage IIIC or IV ovarian carcinoma 
who underwent debulking surgery had a residual 
tumor size of 1 cm or less and had a median 
survival of 36 months.13 On the basis of a previ-
ous EORTC trial of interval debulking surgery, 
median survival among the patients with subop-
timal primary debulking who underwent interval 
surgery was expected to be 26 months.5 Thus, 
the median survival of the whole group of pa-
tients randomly assigned to primary surgery was 
expected to be 31 months. With an accrual time 
of 4 years and a minimum follow-up period of 
3 years, 498 events (704 patients) were required 
to show noninferiority of interval debulking sur-
gery as compared with primary surgery, with a 
one-sided type I error rate of 0.05 and a power of 
80%. A hazard ratio of less than 1.25 was consid-
ered to indicate noninferiority. Secondary end 
points were adverse effects, quality of life, and 
progression-free survival. No interim analyses 
were planned or conducted.
The analysis was planned to be performed 
according to the intention-to-treat principle: all 
randomly assigned patients were included in the 
primary analysis, regardless of whether they were 
eligible and whether they could be evaluated. 
A secondary analysis was based on the treatment 
actually received. For definitions of overall and 
progression-free survival, see the Supplementary 
Appendix. Overall and progression-free survival 
rates were estimated by means of the Kaplan–
Meier method, and overall survival rates in the 
two groups were compared by means of the log-
rank test, with a noninferiority ratio of 0.8. 
Multivariate time-to-event analysis was performed 
with the use of a Cox proportional-hazards 
model and univariate screening followed by a 
stepwise variable-selection procedure.14 Adverse 
events were reported in contingency tables 
with the use of the National Cancer Institute 
Common Toxicity Criteria, version 2.0 (http://
ctep.cancer.gov/protocoldevelopment/electronic_ 
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITA STUDI DI TORINO on October 31, 2012. For personal use only. No other uses without permission. 
 Copyright © 2010 Massachusetts Medical Society. All rights reserved. 
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 363;10 nejm.org september 2, 2010946
670 Underwent randomization
718 Patients were enrolled
48 Were excluded owing to
authorization irregularities
336 Were assigned to primary surgery
315 Received assigned intervention
21 Did not receive assigned intervention
8 (38%) Were withdrawn by physician
3 (14%) Declined to participate
3 (14%) Had different histologic diagnosis 
1 (5%) Died
2 (10%) Had unresectable tumor
3 (14%) Had logistic or administrative
problem
1 (5%) Had unknown reason
315 (94%) Underwent primary debulking
297 (88%) Started chemotherapy
57 (17%) Underwent interval debulking
11 (3%) Underwent second-look procedure
334 Were assigned to neoadjuvant chemotherapy
326 Received assigned intervention
8 Did not receive assigned intervention
3 (38%) Were withdrawn by physician
2 (25%) Declined to participate
1 (13%) Had different histologic diagnosis
1 (13%) Died
1 (13%) Had logistic or administrative 
problem
2 (1%) Underwent primary debulking
326 (98%) Started neoadjuvant chemo-
therapy
295 (88%) Underwent interval debulking
6 (2%) Underwent second-look procedure
3 Were lost to follow-up
78 Discontinued treatment
34 (44%) Had relapse or
died from cancer
16 (21%) Had excessive
toxic effects
1 (1%) Declined treatment
5 (6%) Died from other
causes
2 (3%) Had protocol
violation
18 (23%) Had other reason
2 (3%) Reported no reason
for discontinuing therapy 
5 Were lost to follow-up
71 Discontinued treatment
20 (28%)  Had relapse or
died from cancer
11 (16%) Had excessive
toxic effects
4 (6%) Declined treatment
7 (10%) Died from other
causes
3 (4%) Had protocol
violation
25 (35%) Had other reason
1 (1%) Reported no reason
for discontinuing therapy 
336 Were included in the intention-to-treat analysis 334 Were included in the intention-to-treat analysis
26 Were excluded from per-
protocol analysis
11 Were ineligible
1 Had FNA without pelvic
mass
1 Had wrong disease
stage
3 Had histologic reason
4 Had disabling disease
1 Had prior cancer
1 Had delay of >2 mo
between biopsy and
randomization
1 Did not give enough
information to assess
eligibility
14 Did not start assigned
treatment
12 Were excluded from per-
protocol analysis 
6 Were ineligible
1 Had FNA without pelvic
mass
2 Had FNA, CA-125:CEA 
ratio ≤25, and imaging
not adequate to exclude
other primary tumor
1 Had histologic reason
1 Had disabling disease
1 Signed consent before 
ethical approval
6 Did not start assigned
treatment
310 Were included in the per-protocol analysis 322 Were included in the per-protocol analysis
Figure 1. Numbers of Patients Who Were Enrolled, Randomly Assigned to a Treatment Group, and Included in the Analyses.
CA-125 denotes cancer antigen 125, CEA carcinoembryonic antigen, and FNA fine-needle aspiration. Percentages 
may not total 100% because of rounding.
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applications/docs/ctcv20_4-30-992.pdf); compar-
isons between treatment groups were made with 
the use of the log-rank test for trend. Adverse 
effects were regarded as postoperative if they 
occurred within 28 days after surgery. The largest 
metastases before randomization were measured 
during diagnostic laparoscopy or laparotomy, and 
if neither of these tests was done, their size was 
determined on the basis of CT findings.
R esult s
Characteristics of the Patients  
and Treatment Received
From September 1998 through December 2006, 
a total of 718 patients were enrolled in the study; 
48 patients were excluded because of potential 
authorization irregularities at one institution 
(Fig. 1). The remaining 670 patients were ran-
domly assigned to treatment at 59 institutions 
(median accrual per institution, 5 patients; range, 
1 to 125) (Fig. 1).
The results of the study were similar whether 
the 48 patients from the one center with possi-
ble irregularities were included or excluded. The 
requisite number of events was reached in August 
2008 (median follow-up, 4.7 years).
The baseline characteristics of the patients 
were well balanced between the two treatment 
groups (Table 1). Details regarding residual tu-
mor size, size of largest residual tumor per coun-
try, type of surgery, type of chemotherapy and 
number of courses, and time to initiation (or 
reinitiation) of chemotherapy are summarized in 
Table 1 in the Supplementary Appendix. The 
residual tumor size was 1 cm or smaller after 
primary debulking surgery in 41.6% of patients 
and after interval debulking surgery in 80.6% of 
patients.
After debulking surgery, the primary diagno-
sis changed in 11 patients (3.3%) assigned to 
primary debulking surgery and in 7 patients 
(2.1%) assigned to neoadjuvant chemotherapy 
followed by interval debulking surgery (5 carcino-
sarcomas, 4 endometrial carcinomas, 2 gastro-
intestinal tumors, 2 borderline tumors of the 
ovary, 1 cervical adenocarcinoma, 1 stage IC ovar-
ian carcinoma, 1 teratoma, 1 rhabdomyosarcoma, 
and 1 pseudomyxoma).
The diaphragm, abdominal peritoneum, and 
pelvis (pouch of Douglas, uterus, bladder, rectum, 
and sigmoid) were the most frequent sites of 
residual tumor after both primary debulking and 
interval debulking surgery. Details on the size 
and site of the metastases before and after pri-
mary and interval debulking surgery, as well as 
the debulking rates after interval debulking in 
patients in the primary-surgery group, are sum-
marized in the Supplementary Appendix. Within 
each country, there was a strong correlation be-
tween the rates of optimal debulking at primary 
debulking surgery and at interval debulking sur-
gery (r = 0.92).
Perioperative and Postoperative Morbidity, 
Mortality, and Quality of Life
Perioperative and postoperative morbidity and 
mortality are summarized in Table 1 in the Sup-
plementary Appendix. Postoperative death (de-
fined as death <28 days after surgery) occurred 
in 2.5% of patients in the primary-surgery group 
and in 0.7% of patients in the neoadjuvant-chemo-
therapy group. Grade 3 or 4 hemorrhage occurred 
in 7.4% of patients after primary debulking and 
in 4.1% after interval debulking, infection in 
8.1% and 1.7%, respectively, and venous compli-
cations in 2.6% and 0%, respectively. Analyses 
comparing the perioperative and postoperative 
characteristics of the two groups were not per-
formed because the groups were unequal — that 
is, not all patients who were randomly assigned 
to primary debulking underwent primary debulk-
ing surgery, and not all patients assigned to neo-
adjuvant chemotherapy underwent interval de-
bulking surgery.
At none of the assessment times were the dif-
ferences in the QLQ-C30 global health scores 
significant. The overall test for a treatment ef-
fect on global health was also not significant.
Overall Survival and Progression-free 
Survival
Overall survival was similar in the two groups in 
the intention-to-treat analyses (Fig. 2A), as was 
progression-free survival (Fig. 1 in the Supple-
mentary Appendix). The median overall survival 
was 29 months in the primary-surgery group and 
30 months in the neoadjuvant-chemotherapy group, 
and the median progression-free survival in both 
groups was 12 months. On the basis of the inten-
tion-to-treat analysis, the hazard ratio for death 
in the group assigned to neoadjuvant chemother-
apy followed by interval debulking, as compared 
with the group assigned to primary debulking, 
was 0.98 (90% confidence interval [CI], 0.84 to 
1.13; P = 0.01 for noninferiority), and the hazard 
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ratio for progressive disease was 1.01 (90% CI, 
0.89 to 1.15). The analysis according to treatment 
actually received (per-protocol analysis) showed 
similar results for overall survival (hazard ratio 
for death, 1.00; 90% CI, 0.85 to 1.16; P = 0.01 for 
noninferiority) (Fig. 2 in the Supplementary Ap-
pendix). Figure 2B shows overall survival accord-
ing to treatment group and amount of residual 
tumor (per-protocol analysis). Overall survival in 
the group of patients who underwent primary de-
bulking surgery initially and then interval de-
bulking surgery was similar to that in the group 
of patients who were randomly assigned to neo-
adjuvant chemotherapy (Fig. 3 in the Supplemen-
tary Appendix).
In a post hoc attempt to identify subgroups 
Table 1. Baseline Characteristics of the Patients.
Characteristic
Primary Debulking Surgery
(N = 336)
Neoadjuvant Chemotherapy
(N = 334)
Age — yr
Median 62 63
Range 25–86 33–81
WHO performance status — no. (%)*
0 153 (45.5) 147 (44.0)
1 141 (42.0) 143 (42.8)
2 40 (11.9) 44 (13.2)
Missing data 2 (0.6) 0
Histologic type — no. (%)
Serous 220 (65.5) 194 (58.1)
Mucinous 8 (2.4) 11 (3.3)
Clear-cell 6 (1.8) 4 (1.2)
Endometrioid 11 (3.3) 5 (1.5)
Undifferentiated 69 (20.5) 90 (26.9)
Mixed 3 (0.9) 0
Other or unknown 19 (5.7) 30 (9.0)
Histologic grade — no. (%)
Well differentiated 14 (4.2) 10 (3.0)
Moderately differentiated 57 (17.0) 41 (12.3)
Poorly differentiated 145 (43.2) 130 (38.9)
Unknown 120 (35.7) 153 (45.8)
Stage — no. (%)
IIIC 257 (76.5) 253 (75.7)
IV 77 (22.9) 81 (24.3)
Other 2 (0.6) 0
Malignant pleural effusion — no. (%)
No 285 (84.8) 272 (81.4)
Yes 51 (15.2) 62 (18.6)
Method of biopsy — no. (%)
Laparotomy 12 (3.6) 12 (3.6)
Laparoscopy 104 (31.0) 116 (34.7)
Image guidance 76 (22.6) 53 (15.9)
Fine-needle aspiration 142 (42.3) 153 (45.8)
Missing data 2 (0.6) 0
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of patients in which one of the study treatments 
tended to be associated with better overall sur-
vival, we analyzed the hazard plots in relation to 
age, the International Federation of Gynecology 
and Obstetrics (FIGO) stage, WHO performance 
status, histologic type, and presence or absence 
of pleural fluid (Fig. 4 to 8 in the Supplementary 
Appendix). In none of the subgroups was there 
apparent superiority of one of the treatments. 
When we evaluated the outcome of debulking to 
1 cm or less according to country, no significant 
differences were noted between the treatment 
groups (Fig. 9 in the Supplementary Appendix). 
When the patients who were randomly assigned 
by the EORTC-GCG (586 patients) were compared 
with those randomly assigned by the NCIC Clini-
cal Trials Group (84 patients), the median overall 
survival was similar (28 and 34 months, respec-
tively). This result is noteworthy, since the pro-
portions of patients with no residual tumor after 
primary de bulking surgery and after interval deb-
ulking surgery tended to be higher in the sub-
group randomly assigned by the EORTC-GCG 
(20.4% and 50.0%, respectively) than in the sub-
Table 1. (Continued.)
Characteristic
Primary Debulking Surgery
(N = 336)
Neoadjuvant Chemotherapy
(N = 334)
Primary tumor — no. (%)
Epithelial ovarian 293 (87.2) 283 (84.7)
Peritoneal 22 (6.5) 26 (7.8)
Fallopian tube 0 4 (1.2)
Adenocarcinoma 17 (5.1) 20 (6.0)
Missing data 4 (1.2) 1 (0.3)
Serum CA-125 at entry (U/ml)
Median 1130 1180
Range 16.0–27,185 15.0–41,456
Serum CA-125 >30 U/ml — no. (%) 330 (98.2) 330 (98.8)
Largest metastatic tumor at randomization — no. (%)
0 cm 2 (0.6) 1 (0.3)
>0–2 cm 2 (0.6) 9 (2.7)
>2–5 cm 90 (26.8) 85 (25.4)
>5–10 cm 90 (26.8) 88 (26.3)
>10–20 cm 105 (31.3) 113 (33.8)
>20 cm 26 (7.7) 24 (7.2)
Missing data 21 (6.3) 14 (4.2)
Size of metastases at the time of surgery — no. (%)†
No metastasis 1/310 (0.3) 14/322 (4.3)
>0–1 cm 2/310 (0.6) 36/322 (11.2)
>1–2 cm 14/310 (4.5) 40/322 (12.4)
>2–5 cm 50/310 (16.1) 74/322 (23.0)
>5–10 cm 40/310 (12.9) 42/322 (13.0)
>10 cm 191/310 (61.6) 78/322 (24.2)
Missing data 12/310 (3.9) 38/322 (11.8)
* WHO denotes World Health Organization.
† The per-protocol population included only eligible patients who actually underwent primary debulking surgery in the 
primary-surgery group (310 patients) and patients who actually started chemotherapy in the neoadjuvant-chemotherapy 
group (322).
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group assigned by the NCIC Clinical Trials Group 
(11.1% and 40.5%, respectively). Among patients 
with metastatic tumors that were less than 5 cm 
in diameter at randomization, overall survival was 
slightly longer in the primary-surgery group than 
in the neoadjuvant-chemotherapy group (hazard 
ratio, 0.64; 95% CI, 0.45 to 0.93) (Fig. 10 in the 
Supplementary Appendix).
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Figure 2. Overall Survival in the Intention-to-Treat Population and Overall Survival According to Treatment Received 
and Status with Respect to Residual Tumor.
The median overall survival was 29 months among the women assigned to primary debulking surgery and 30 
months among those assigned to neoadjuvant chemotherapy (Panel A). The median overall survival for women with 
no residual tumor (optimal result), those with residual tumors that measured 1 to 10 mm in diameter (suboptimal 
result), and those with residual tumors larger than 10 mm (other result) was 45, 32, and 26 months, respectively, in 
the group that underwent primary debulking surgery and 38, 27, and 25 months, respectively, in the group that un-
derwent neoadjuvant chemotherapy (Panel B).
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Multivariate Analyses
Unadjusted and adjusted Cox regression multi-
variate analyses were performed post hoc, with 
overall survival as the end point, and included 
the following variables: largest residual tumor 
after primary or interval debulking surgery, larg-
est tumor size before randomization, WHO per-
formance status, age, FIGO stage, histologic type, 
method of biopsy, histologic grade, treatment 
group, and country (reduced to eight categories 
by pooling results from the smallest seven coun-
tries). The strongest independent predictors of 
prolonged survival, in descending order, were the 
absence of residual tumor after surgery (P<0.001); 
stage IIIC disease (P = 0.001); small tumor size 
before randomization (P = 0.001); endometrioid 
histologic type, followed in descending order by 
serous, mixed, undifferentiated, mucinous, and 
clear-cell types (P = 0.005); and younger age 
(P = 0.005). The other variables did not signifi-
cantly influence overall survival.
Discussion
In this randomized trial, primary debulking sur-
gery followed by chemotherapy was compared 
with neoadjuvant chemotherapy followed by in-
terval debulking surgery in women with advanced 
ovarian cancer. We found that survival after neo-
adjuvant chemotherapy followed by interval de-
bulking surgery was similar to survival with the 
standard approach of primary surgery followed 
by chemotherapy.
This trial did not include patients with FIGO 
stage IIIB or earlier-stage ovarian carcinoma. 
Rather, all the study participants had extensive 
stage IIIC or IV disease. Indeed, most patients 
had obvious stage IIIC or IV disease; at the time 
of primary debulking surgery, 61.6% had meta-
static lesions that were larger than 10 cm in di-
ameter, and 74.5% had lesions larger than 5 cm. 
This is noteworthy, since it might be the reason 
for the poor outcomes with respect to median 
progression-free and overall survival, as com-
pared with the findings in some single-institu-
tion series13,15-18; however, the debulking rates 
and survival rates in our study are similar to 
those in other multicenter or regional studies 
that analyzed stage IIIC and IV ovarian carcino-
mas separately.19-25 Furthermore, the current study 
showed no trend in favor of primary debulking 
in countries with high rates of optimal primary 
debulking surgery. This finding might be due to 
the strong correlation between cytoreduction 
rates at primary debulking surgery and at inter-
val debulking surgery within each country.
In selecting patients for neoadjuvant chemo-
therapy, it is important to rule out other primary 
tumors, especially those of gastrointestinal ori-
gin. In this study, a CA-125:CEA ratio higher 
than 25 was used as an eligibility criterion, since 
this ratio has been shown to be a good tool for 
ruling out primary gastrointestinal tumors that 
have metastasized to the peritoneum or ovaries 
or to both sites.9 The value of this ratio was 
confirmed in the current study, since only two 
patients proved to have a gastrointestinal cancer 
at the time of primary or interval debulking 
surgery.
Complete resection of all macroscopic disease 
at primary debulking surgery has been shown 
to be the single most important independent 
prognostic factor in advanced ovarian carcino-
ma.13,15-18,25,26 In the current study, the impor-
tance of this prognostic factor was confirmed by 
the results of the multivariate analyses and the 
survival analyses according to the extent of re-
sidual tumor after both primary and interval de-
bulking surgery (Fig. 2B). Given our findings and 
the results of other studies, a potential approach 
for debulking surgery could be the elimination of 
all macroscopic residual disease, rather than the 
elimination of lesions larger than 1 cm in diam-
eter. A potential drawback of neoadjuvant chemo-
therapy followed by debulking surgery is that the 
occurrence of fibrosis after chemotherapy may 
make complete resection of macroscopic disease 
more difficult.
In conclusion, among patients with advanced 
(stage IIIC or IV) ovarian, fallopian-tube, or peri-
toneal ovarian carcinoma, survival after neoad-
juvant chemotherapy followed by interval debulk-
ing surgery is similar to survival after primary 
debulking surgery followed by chemotherapy. 
This result is consistent with the conclusions of a 
recent meta-analysis of 21 nonrandomized trials.27 
The standard of care for women with stage IIIB 
or earlier-stage epithelial ovarian cancer — a 
group with a better prognosis than the current 
study population — remains primary cytoreduc-
tive surgery. Only those patients with proven 
stage IIIC or IV disease should be considered for 
neoadjuvant chemotherapy.
In the current study, none of the subgroup 
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analyses showed a significant difference in sur-
vival between the two treatment groups. When 
deciding whether a patient is a candidate for pri-
mary debulking surgery, with an acceptable level 
of morbidity, the clinician may consider taking 
into account information from the surgical con-
sultation and could assess important predictive 
factors with respect to residual macroscop ic dis-
ease after debulking surgery (e.g., presence or 
absence of coexisting illnesses, age, disease bur-
den, location of metastatic sites, WHO perfor-
mance status, and tumor stage). Laparoscopy, in 
addition to axial CT, positron-emission tomogra-
phy, or both,28 may provide information about 
the disease burden.29-32 Neoadjuvant chemother-
apy is not inferior to primary cytoreductive sur-
gery for patients with stage IIIC or IV ovarian 
carcinoma. No significant advantages of neoad-
juvant therapy or primary debulking surgery were 
observed with respect to survival, adverse effects, 
quality of life, or postoperative morbidity or 
mortality.
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